14-day Premium Trial Subscription Try For FreeTry Free
Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.
Upgrades According to DA Davidson, the prior rating for Helen Of Troy Ltd (NASDAQ:HELE) was changed from Neutral to Buy. Helen Of Troy earned $2.27 in the second quarter, compared to $2.65 in the year
Upgrades For NRG Energy Inc (NYSE:NRG), B of A Securities upgraded the previous rating of Underperform to Neutral. For the third quarter, NRG Energy had an EPS of $0.29, compared to year-ago quarter E
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52

7 Analysts Have This to Say About Glaukos

07:02pm, Monday, 12'th Dec 2022 Benzinga
Glaukos (NYSE:GKOS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 2 1 0 Last 30D 1 0 1

Analyst Ratings for Glaukos

06:01pm, Monday, 12'th Dec 2022 Benzinga
Analysts have provided the following ratings for Glaukos (NYSE:GKOS) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 2 1 0 Last 30D
Upgrades For Colliers International Group Inc (NASDAQ:CIGI), Goldman Sachs upgraded the previous rating of Neutral to Buy. Colliers Intl Gr earned $1.41 in the third quarter, compared to $1.27 in the

Where Glaukos Stands With Analysts

12:04pm, Monday, 12'th Dec 2022 Benzinga
Glaukos (NYSE:GKOS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 1 1 0 Last 30D 1 0 0

Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?

04:31pm, Friday, 02'nd Dec 2022 Zacks Investment Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

03:26pm, Wednesday, 23'rd Nov 2022 Zacks Investment Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos Corporation (NYSE:GKOS ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Chris Lewis - Vice President-Investor Relations & Corporate Affairs Tom Burns - Chair
U.S. stocks closed lower on Thursday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. Lincoln National Corporation (NYS

What 4 Analyst Ratings Have To Say About Glaukos

01:26pm, Thursday, 03'rd Nov 2022 Benzinga
Analysts have provided the following ratings for Glaukos (NYSE:GKOS) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D
Glaukos' (GKOS) Q3 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE